Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

132.14
Delayed Data
As of Jul 29
 -3.28 / -2.42%
Today’s Change
83.16
Today|||52-Week Range
140.72
+18.13%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$107.4B

Company Description

Celgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Contact Information

Celgene Corp.
86 Morris Avenue
Summit New Jersey 07901
P:(908) 673-9000
Investor Relations:
(908) 673-9969

Employees

Shareholders

Mutual fund holders43.65%
Other institutional39.99%
Individual stakeholders1.22%

Top Executives

Robert J. HuginChairman & Chief Executive Officer
Mark J. AllesPresident & Chief Operating Officer
Peter N. KelloggChief Financial Officer & Executive Vice President
Jerome Bernard ZeldisChief Medical Officer & CEO-Global Health
Thomas O. DanielEVP, President-Research & Early Development